U.S. Markets close in 5 hrs 6 mins

Edited Transcript of XXII earnings conference call or presentation 8-Aug-19 8:00pm GMT

Q2 2019 22nd Century Group Inc Earnings Call

WILLIAMSVILLE Aug 16, 2019 (Thomson StreetEvents) -- Edited Transcript of 22nd Century Group Inc earnings conference call or presentation Thursday, August 8, 2019 at 8:00:00pm GMT

TEXT version of Transcript


Corporate Participants


* Clifford B. Fleet

22nd Century Group, Inc. - CEO, President & Director

* John T. Brodfuehrer

22nd Century Group, Inc. - CFO & Treasurer

* Thomas L. James

22nd Century Group, Inc. - VP, General Counsel & Secretary




Operator [1]


Good day and welcome to the 22nd Century Second Quarter 2019 Business Update Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Thomas James. Please go ahead, sir.


Thomas L. James, 22nd Century Group, Inc. - VP, General Counsel & Secretary [2]


Thank you very much. My name is Thomas James, the Vice President, General Counsel and Secretary of the company. We thank everybody for joining the call, and I appreciate you bearing with us as we read the required Safe Harbor text. The statements made on today's call that are not based on historical information are forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our company's business strategy, future plans and objectives and future results of operations or that may predict, forecast, indicate or imply future results, performance or achievements. The words project, intend, forecast, anticipate, plan, expect, believe, will, will likely, should, may or the negative of such words, or words or expressions of similar meanings are all intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, and all such forward-looking statements involve risks and uncertainties, many of which are beyond our company's ability to control. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, the risk factors disclosed in our company's most recent annual report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on March 6, 2019.

22nd Century does not undertake and it disclaims any obligation to update any forward-looking statements. Our announce revisions to any of the forward-looking statements. During this conference call, we will also disclose certain non-GAAP financial measures, including adjusted EBITDA, which we define as earnings before interest, taxes, depreciation and amortization as adjusted by 22nd Century for certain noncash and nonoperating expenses. All is described in our company's earnings press release for the quarter ended June 30, 2019, as publicly issued yesterday on August 7, 2019, and which is available in our company's website.

And with that, we'd like to now turn it over -- the call to Cliff Fleet, the company's Chief Executive Officer.


Clifford B. Fleet, 22nd Century Group, Inc. - CEO, President & Director [3]


Thank you, Tom. And thanks to everyone for joining today's call. I am pleased to be here to discuss 22nd Century. It's performance and what we believe are the companies bright prospects. I am excited to serve the company as its newly appointed CEO, and I look forward to working with our shareholders, employees and other, to continue building a great business, by driving historic change in the tobacco industry to reduce the harm caused by smoking and by creating a meaningful and profitable business in the emerging legal hemp/cannabis space. We believe the pursuit of these growth strategies for which we are very well positioned, will create substantial value for shareholders.

Before we proceed, let me tell you a few -- tell you about a few changes to the format of the call. I will talk about the company strategies, plans and overall performance and then John, our Chief Financial Officer, will review highlights of the company's operational and financial performance for the second quarter and first half of 2019. We will no longer be taking questions from individual shareholders during the call. However, our Investor Relations team will be happy to address your questions personally after the call. We thank those shareholders and others who submitted questions to us in advance of the call, and we have addressed many of those questions in our communications today. We expect the call to last about 30 minutes. With that, let's begin.

As the company recently announced, Henry resigned as president, CEO and Board member of 22nd Century for personal reasons. We are thankful for his leadership and contributions to the company over the past several years as it made tremendous progress to get its mission to help reduce the harm caused by smoking and we are grateful that his expertise, advice and counsel, is retained in a consultative capacity to the company. Also as announced earlier this week, I have recently joined the company as president, CEO and a Member of the Board of Directors. As explained more fully in that announcement, my background is in Consumer Packages goods, particularly tobacco and primarily with Altria, the leading tobacco company in the U.S. where I was the President and CEO of Philip Morris USA, until 2017. Since then, I have worked as an advisor and consultant to several startups, high growth businesses and nonprofits. But none prove more interesting than my work with this company.

Several months ago, I begin working with 22nd Century as a strategic advisor because I was intrigued by the work the company has done in both tobacco and hemp/cannabis. I was impressed by the potential of the organization and I found it exciting to work with the company's board and executive team to develop and refine the company strategies to capitalize on its potential. I was flattered and honored when the board then asked me to step into a leadership role to drive the company forward.

The success of any organization is predicated upon the strength of its leadership team. And recently the company made another move of great importance with it's elevation of Mike Zercher to the role of Chief Operating Officer, which strengthens what was already a solid leadership team. He has had tremendous success over the course of his career and a variety of domestic and international roles. Mike serves as a vital leader in the organization, as we implement our reshape strategies and pursue the opportunity before us. I am privileged to work with him, the board and all of our talented employees as we enter the next chapter of growth for the company.

We believe the company's prospects are very bright as we leverage solid foundations in 2 industries, tobacco and hemp/cannabis to create future shareholder value. We are very well positioned in tobacco, as FDA continues moving towards the adoption of a reduced nicotine products standard, that will require all combustible cigarettes sold in the U.S. to contain only minimally or nonaddictive levels of nicotine.

Moreover, as a recently published survey from the CDC found 80% of cigarette smokers and 84% of former smokers are in favor of reducing nicotine levels in cigarettes. Clearly, many smokers believe as we do along with many in the public health community that the adoption of this standard is critical to reduce the harm caused by smoking, and so we continue to work to support the efforts of FDA and others to implement this historic change.

We have worked with scientists, clinicians, regulators and others for many years to build the now substantial body of science and evidence to prove conclusively, the public health benefits of this proposed standard. We estimate that over the past 7 years, FDA and other U.S. federal government agencies have invested more than $125 million in research, using our spectrum research cigarettes. We believe this research conclusively makes the case that minimally or nonaddictive levels of nicotine in cigarettes will significantly reduce the harm caused by smoking, both in our own products and when required for all combustible cigarettes.

Our tobacco harm reduction efforts also include the recently filed and very important premarket tobacco product and Modified Risk Tobacco Product applications for the company's proprietary very low nicotine content cigarettes. With these applications, we are seeking FDA's authorization to commercialize our VLN branded cigarettes, which contain 95% less nicotine as compared to the 100 leading brands of cigarettes in the U.S.

These applications have been accepted by FDA and are now working their way through FDA's scientific review. Earlier this year, as part of that review, FDA inspected our manufacturing facility, where VLN cigarettes will be made. In addition, we continue to have ongoing constructive dialogues with FDA regarding these applications.

We are only the fifth company to have a Modified Risk Tobacco Product application accepted for filing by FDA. And to date, FDA has yet to approve any of those applications. However, we believe approvals of both our PMT and MRTP applications are likely because the products in these applications are identical to the Very Low Nicotine Content research cigarettes used in the FDA sponsored research that I previously highlighted, which underpins the FDA's proposed reduced nicotine standard.

Also we believe, along with many others that these products are of critical importance to FDA's regulatory path for nicotine, and for the adoption of a reduced nicotine product standard. So we remain optimistic about their ultimate approval.

The adoption of the reduced nicotine product standard and the approval of our VLN branded products are central to achieving 22nd Century's mission to reduce the harm caused by smoking and to create shareholder value.

So we will continue making appropriate investments in these efforts. We continue to develop additional varieties of very low nicotine tobacco, including non-GMO varieties, and we have enhanced of regulatory affairs and scientific capabilities with the addition of John Pritchard, as Vice President of Regulatory Science, who was formerly the Head of Regulatory Science for Imperial Brands U.K. We're actively engaging with various stakeholders around the world to build awareness about proprietary very low nicotine content cigarettes. Our plans to bring these to market and FDA's plans require all cigarettes sold in the U.S. to be made minimally or nonaddictive. We believe these efforts will bring about significant benefits to public health and will also create shareholder value. Thus, we will continue to pursue these efforts with vigor and energy as we has -- as we have over the past few years.

And what is exciting about our future is that tobacco is just one of the ways we will create value. We believe that by building on our strong ways in hemp/cannabis, we have another exciting and potentially even more valuable path for growth. The legal hemp/cannabis space in U.S. has centered around products derived from the hemp/cannabis plant, which is legally defined as cannabis containing less than 0.3% THC. We believe the value of the legal hemp/cannabis products market currently totals $1 billion to $2 billion per year, while not a large market today, but the 2018 Farm Bill legalizing all parts of the hemp plant, and with the rapid growth of CBD products, the hemp/cannabis market is believed to be growing faster than even the marijuana industry. Because of this, the value of the hemp/cannabis market could suppress the combined value of the medical and adult-use marijuana markets in just a few years. And because this is a very new, fragmented market, there are no well-established companies and brands.

Rapidly growing spaces with these characteristics present tremendous opportunities for companies, who approach such opportunities in a thoughtful manner that builds upon their existing strengths, and we have many strengths that were value to this emerging space that we plan to leverage to create shareholder value.

22nd Century has what we believe to be a strong position, centered on the genetic pathways of cannabinoid production and hemp/cannabis plants that we can leverage for growth. We also bring other strategic assets to this fast-growing category, such as world-class regulatory affairs capabilities, including with FDA and deep expertise in consumer package through the branding, marketing and sales. We are seeking the right relationships with emerging organization in the hemp/cannabis market to leverage these strengths and create long-term value for our shareholders.

Our work in this space began several years ago, with our investment in Anandia, which was purchased by Aurora last year. After this purchase, we retained all rights to the research in intellectual property developing with Anandia, this includes the exclusive sublicense to the company that allows us to regulate the genes and hemp/cannabis plant as well as the rights to zero-THC hemp plants and other valuable cannabis strains. We're in the process of making of important, thoughtful and comprehensive investments that add to this strong ways. And strengthen our leadership position around hemp/cannabis plant genetics. We have obtained a license from the State of New York to researching grow hemp in the space. We're in a server internal research efforts with a new research lab an additional personnel. We're building a research growing facility including in the House in Oregon to support our work in hemp/cannabis. And earlier this year we signed an exclusive worldwide multiyear agreement with Keygene NV. Keygene is a global leader in plant research involving high-value genetic and agronomic traits. We have partnered with Keygene to hemp/cannabis plant with valuable cannabinoid profiles and others superior agronomic traits. We will hold exclusive worldwide rights to all hemp/cannabis plant lines, intellectual property and research results that are developed through this exciting and promising relationship.

We believe, these efforts to create new plants and IP in conjunction with other steps that we will take in the future to strengthen our current leadership position in hemp/cannabis plant genetics. We will make 22nd Century a sought after partner and source for unique plants and high-value cannabinoid extracts in these plants. But we aspire to do more, so we're carefully looking at a variety of other ways to become a major player in this emerging space. We plan to opportunistically create shareholder value through partnerships, investments and other strategic relationships across the entire hemp/cannabis value chain, including branded consumer product. We are thoughtfully surveying the landscape, and evaluating companies, assets and organizations, with the goal of building a platform to drive our growth in this fast-growing an exciting category.

In summary, we feel very good about 22nd Century's position and prospects. We're actively working with FDA and others to implement a new agency rule, requiring that all cigarettes sold in the U.S. contain only minimally or nonaddictive levels of nicotine.

We have successfully filed PMT and MRTP applications, which are under review by FDA. We are expanding our strong position built around our hemp/cannabis intellectual property portfolio. We're evaluating opportunities to increase our presence in hemp/cannabis genetics and we are seeking ways to grow into other areas of the fast-growing hemp/cannabis value chain. Given the many opportunities before us, it is indeed an exciting time for the company. I look forward to working with our very talented team, our business partners, our shareholders and others. To seize these opportunities and grow our business. I would now like to turn the call over to John for comments on our operating and financial performance for the second quarter and first half of the year.


John T. Brodfuehrer, 22nd Century Group, Inc. - CFO & Treasurer [4]


Thank you, Cliff. I'm going to offer perspectives and highlights on our second quarter and first half performance for 2019. Details about our company's performance can be found in our earnings release and quarterly Form 10-Q both issued yesterday. All financial comparisons in my remarks are against the comparable year ago time period, unless otherwise noted.

Our financial position remains solid with the maintenance of a strong balance sheet and good liquidity to fund operations, meet obligations as they become due to fund our research and development and make other potential investments. Our income performance deteriorated from the prior year period due to the factor I will address in a moment and our underlined cash utilization rate also increased for the first half of 2019 versus the year-ago comparable time period. Our cash utilization improved slightly for the second quarter of 2019 versus the year ago comparable time period.

We expect the comparable numbers for income and cash burn to remain relatively constant as the year progresses, although, we remain optimistic for potential improvement as a result of possible investments to strengthen our business platform for the long-term, which may impact our company's use of cash and its liquidity position.

For both the 3- and 6-month periods, net sales revenue decrease from the comparable prior year periods. For the second quarter, net sales revenue decreased by 15.9% to $5.8 million, while in the first half of the year, net sales revenue decreased by 7.1% to $12.1 million. This decrease in both periods was principally driven by a decrease in production volume in our contract manufacturing business in-line with industry trends.

Our cost of goods sold increased in both time periods as a percentage of net sales revenue, principally driven by an increase in fees due to the FDA for filtered cigars as well as higher labor and equipment maintenance costs. These costs increases resulted in a slight gross loss on sales during both the second quarter and the first half versus a slight gross profit in both periods last year.

As context, we maintain our manufacturing operations to produce our spectrum research cigarettes and in anticipation of the FDA's approval of our proprietary VLN branded MRTP cigarettes. In the interim, our contract manufacturing business continues to absorb much of our excess manufacturing capacity and overhead. Also -- while tobacco product contract manufacturing is a price competitive business, we are working diligently to bring our manufacturing cost down to return to a gross profit position on sales.

We are also prudently managing our operating expenses, for example, research and development expense for the company decreased in both time periods as the expenses related to tobacco broadly declined, while expense related to hemp/cannabis increased, reflecting the shift in strategic priorities of the company.

Last year, the company incurred significant expenses related to its PMT and MRTP applications. While this year, we've increased spending to support work in hemp/cannabis, with additional investments in regulatory operations and sponsored research. General and administrative expenses were up in both time periods, given a variety of factors.

We are going to keep a careful eye on these to ensure we are thoughtful and disciplined.

As a result, and due to items I have already discussed as well as other items more fully explained in our earnings press release and in our second quarter Form 10-Q filing, 22nd Century had net losses in both time periods this year that were greater than net losses experienced for the comparable year ago time periods. For the second quarter, the primary reason for the net loss was a noncash expense of $1.9 million, relating to the Crede lawsuit settlement in an unrealized loss in our investment in Aurora Cannabis stock warrants of $1.4 million. Although, the fair value of these stock warrants was at -- was positive at over $4.6 million at quarter end. For the first half of 2018, we recorded a significant unrealized gain on our investment related to Anandia. The decrease in this unrealized gain coupled with the Crede settlement expense were the main reasons for the increased net loss during the first half of 2019.

Our liquidity position remained strong, and we believe our cash, cash equivalents and short-term investments are adequate to meet our needs for a number of years. However, we must successfully execute our business plan to achieve positive cash flows, which we are working hard to do.

Excluding discretionary expenses, such as future acquisitions or equity investments, research and development, FDA applications, contract growing and various other items, our monthly cash expenditures are approximately $1.1 million. We expect that this monthly cash expenditure figure should improve over time as our business growth plan delivers higher revenues and as we thoughtfully manage our expenses.

In summary, our financial position remains strong, and we are making thoughtful and necessary investments to strengthen our position in tobacco and hemp/cannabis. Our strong liquidity position will enable the company to be opportunistic as we seek future growth opportunities. Thank you.


Thomas L. James, 22nd Century Group, Inc. - VP, General Counsel & Secretary [5]


We thank everyone for joining our call today. Listeners with questions may contact our Investor Relations department through our website. We wish everyone a very good evening.


Operator [6]


Thank you, ladies and gentlemen. This concludes today's event. You may now disconnect your lines.